ОСОБЕННОСТИ ГИПОЛИПИДЕМИЧЕСКОГО И ПЛЕЙОТРОПНОГО ДЕЙСТВИЯ СТАТИНОВ У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА

Aim: To study influence of rosuvastatine and atorvastatine treatment (3 months) on apolipoproteine level and inflammation markers at unstable angina patients. Material and methods. In comparative randomised crossover open research 74 patients with unstable angina (II B class, Braunwald classification) at the age of 35–74 years, with cholesterol low density level (LDL) > 100 mg/dl. To half of patients were appointed atorvastatine treatment 20 mg/day which in the absence of achievement of target level LDL <100 mg/dl after 1 month, increased to 40 mg/day; other half received rosuvastatine 10 mg/day, with its increase to 20 mg/day, in the absence of effect in 1 month. The lipids, apolipoproteine, high-sensitivity C-reactive proteine levels were determined on biochemical autoanalyzer “Daytоna” (RANDOX). Results. After atorvastatine (3 months) (I group) and rosuvastatine treatment (II group) were observed decrease of the total cholesterol, LDL cholesterol level and triglycerides; target LDL cholesterol level<100 mg/dl has been reached in 56 % and 60 % of cases, accordingly. However, increase of HDL cholesterol level (Р <0,01) and more significant decrease in coefficient atherogeneity (Р <0,01) was accompanied at rosuvastatine treatment in comparison with I group. Apolipoproteine B level has decreased on 8,9 % (p<0,01) in I and on 10,6 % (p <0,05) in II group, that also was significantly lower at rosuvastatine treatment (p <0,01). Simultaneously rosuvastatine treatment was accompanied by increase of Apolipoproteine A level on 16 % (Р <0,001) and more significant decrease of Apo B/Apo A ratio - on 25 % (p <0,001) in comparison with atorvastatine. Both rosuvastatine and atorvastatine treatment were accompanied by decrease of high-sensitivity C-reactive proteine level (p<0,001). The conclusion. The increase in concentration of HDL cholesterol level and more significant decrease of Apo B/Apo A ratio at rosuvastatine treatment expands possibilities of its application in clinical practice, especially at patients with high risk of cardiovascular complications.